

# Cardiovascular Disease Prevention

## *Bibliography of One Hundred Key Papers*

selected by **David A. Wood, MSc, FRCPE, FFPHM, FESC and Kornelia Kotseva, MD, PhD, FESC**

*Cardiovascular Medicine - National Heart and Lung Institute (NHLI) - Imperial College London  
London - UK*

- 
- ACE Inhibitor Myocardial Infarction Collaborative Group.** *Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100 000 patients in randomized trials.*  
**Circulation.** 1998;97:2202-2212.
- 
- Advisory Board of the International Heart Health Conference.** *The Victoria Declaration: On Heart Health.*  
**In: Declaration of the Advisory Board of the International Heart Health Conference 1992.** Victoria, British Columbia, Canada. 1992.
- 
- Advisory Board of the Second International Heart Health Conference.** *The Catalonia Declaration: investing in heart health.*  
**In: Declaration of the Advisory Board of the Second International Heart Health Conference 1996.** Barcelona, Spain: Catalonia, Spain. 1996.
- 
- Allender S, Scharbotough P, Peto V, et al.** **European Cardiovascular Disease Statistics.** 2008 edition. London, UK: British Heart Foundation 2008.
- 
- Anand SS, Yusuf S.** *Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.*  
**JAMA.** 1999; 282: 2058-67.
- 
- Anderson KM, Odell PM, Wilson PW, Kannel WB.** *Cardiovascular disease risk profiles.*  
**Am Heart J.** 1991;121(1 pt 2):293-298.
- 
- Anderson KM, Wilson PW, Odell PM, Kannel WB.** *An updated coronary risk profile. A statement for health professionals.*  
**Circulation.** 1991;83:356-362.
- 
- Antithrombotic Trialists' Collaboration.** *Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk people.*  
**BMJ.** 2002;324:71-86.
- 
- Bartnik M, Ryden L, Ferrari R, et al; Euro Heart Survey Investigators.** *The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.*  
**Eur Heart J.** 2004;25:1880-1890.
- 
- Bhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators.** *International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis.*  
**JAMA.** 2006;295:180-189.
-

**Bibliography of One Hundred Key Papers**

---

- Blood Pressure Lowering Treatment Trialists' Collaboration.** *Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration.*  
**Lancet.** 2003;362:1527-1535.
- 
- British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association.** *Joint British Societies' Guidelines on Prevention of Cardiovascular Disease in Clinical Practice.*  
**Heart.** 2005;91(suppl V):V1-V52.
- 
- Bucher HC, Hengstler P, Schindler C, Meier G.** *N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.*  
**Am J Med.** 2002;112:298-304.
- 
- Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis In Myocardial Infarction 22 Investigators.** *Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE-IT).*  
**N Engl J Med.** 2004;350:494-504.
- 
- Cholesterol Treatment Trialists' (CTT) Collaboration.** *Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.*  
**Lancet.** 2005;366:1267-1278.
- 
- Conroy RM, Pyorala K, Fitzgerald AP, et al.** *Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.*  
**Eur Heart J.** 2003;24:987-1003.
- 
- Danchin N, Hanania G, Grenier O, et al.** *Evolution du traitement de sortie après hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000: données des études Usik 1995, Prevenir 1 et 2 et Usic 2000. [Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].*  
**Ann Cardiol Angeiol.** 2003;52:1-6.
- 
- De Backer G, Ambrosioni E, Bort-Johnsen K, et al.** *European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice.*  
**Eur J Cardiovasc Prev Rehab.** 2003;10(suppl 1):S1-S78.
- 
- de Lemos JA, Blazing MA, et al; A to Z Investigators.** *Early intensive vs a delayed conservative simvastatin strategy in people with acute coronary syndromes: phase Z of the A to Z trial.*  
**JAMA.** 2004;292:1307-1316.
- 
- De Velasco JA, Cosin J, Lopez-Sendon JL, De Teresa E, De Oya M, Sellers G.** *Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II. [New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study].*  
**Rev Esp Cardiol.** 2002;55:801-809.
- 
- De Velasco JA, Cosin J, Lopez-Sendon JL, et al.** *La prevención secundaria del infarto de miocardio en España. Estudio PREVESE (Secondary prevention of myocardial infarction in Spain. The PREVESE study).*  
**Rev Esp Cardiol.** 1997;50:406-415.
- 
- Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA.** *Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials.*  
**J Am Coll Cardiol.** 1999;33:598-604.
-



- 
- Ebrahim S, Beswick A, Burke M, Davey Smith G.** *Multiple risk factor interventions for primary prevention of coronary heart disease.* **Cochrane Database of Systematic Reviews.** 2006.
- 
- [ec.europa.eu/health/ph\\_determinants/life\\_style/nutrition/documents/nutrition\\_gp\\_en.pdf](http://ec.europa.eu/health/ph_determinants/life_style/nutrition/documents/nutrition_gp_en.pdf)
- 
- EUROASPIRE Study Group.** *EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results.* **Eur Heart J.** 1997;18:1569-1582.
- 
- EUROASPIRE Study Group.** *Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries.* **Lancet.** 2001;357:995-1001.
- 
- EUROASPIRE Study Group.** *Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme.* **Eur Heart.** 2001;22:554-572.
- 
- EUROPA Investigators.** *The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among people with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).* **Lancet.** 2003;362:782-788.
- 
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.** *Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).* **JAMA.** 2001;285:2486-2497.
- 
- Flack J, Neaton J, Grimm R, et al; Multiple Risk Intervention Trial Research Group.** *Blood pressure and mortality among men with prior myocardial infarction.* **Circulation.** 1995;92:2437-2445.
- 
- Fonarow G, French W, Parsons L, Sun H, Malmgren J; National Registry of Myocardial Infarction 3 Participants.** *Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.* **Circulation.** 2001;103:38-44.
- 
- Fourth International Heart Health Conference.** *The Osaka Declaration: Health, Economics and Political Action: Stemming the Tide of Cardiovascular Disease.* **In: Declaration of the Fourth International Heart Health Conference 2001.** Osaka, Japan.
- 
- Fox KAA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G; ENACT (European Network for Acute Coronary Treatment) Investigators.** *The ENACT study: a pan-European survey of acute coronary syndromes.* **Eur Heart J.** 2000; 21:1440-1449.
- 
- Fox KAA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A; GRACE Investigators.** *Management of acute coronary syndromes. Variations in practice and outcome.* **Eur Heart J.** 2002;23:1177-1189.
- 
- Freemantle N, Cleland J, Young P, Mason J, Harrison J.** *β-Blockade after myocardial infarction: systematic review and meta regression analysis.* **BMJ.** 1999;318:1730-1737.
-

**Bibliography of One Hundred Key Papers**

---

- Gaede P, Vedel P, Larsen N, Jensen GV, Parving H, Pedersen O.** *Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.* **N Engl J Med.** 2003;348:383-393.
- 
- Ghandehary H, Kamal-Bahl S, Wong ND.** *Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004.* **Am Heart J.** 2008;156:112-119.
- 
- Graham I, Atar D, Borch-Johnsen K, et al.** *European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice in Clinical Practice (Constituted by representatives of nine societies and by invited experts).* **Eur J Cardiovasc Prev Rehabil.** 2007;14(suppl 2):S1-S113. Executive summary: **Eur J Cardiovasc Prev Rehabil.** 2007;14(suppl 2):E1-E40; **Eur Heart J.** 2007;28:2375-2414.
- 
- Gustafsson I, Hildebrandt P, Selbaek M, et al.** *Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group.* **Eur Heart J.** 2000;21:1937-1943.
- 
- Haskell WL, Alderman EL, Fair JM, et al.** *Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).* **Circulation.** 1994;89:975-990.
- 
- Heart Protection Study Collaborative Group.** *MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.* **Lancet.** 2002;360:7-22.
- 
- Heidrich J, Behrens T, Raspe F, Keil U.** *Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany.* **Eur J Cardiovasc Prev Rehab.** 2005;12:521-529.
- 
- Hobbs R, Erhardt L.** *Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey.* **Fam Practice.** 2002;19:596-604.
- 
- Jackson R.** *Updated New Zealand cardiovascular disease risk-benefit prediction guide.* **BMJ.** 2000;320:709-710.
- 
- Jackson R, Barham P, Bills J, et al.** *Management of raised blood pressure in New Zealand: a discussion document.* **BMJ.** 1993;307:107-110.
- 
- Jolliffe JA, Rees K, Taylor RS, et al.** *Exercise-based rehabilitation for patients with coronary heart disease.* **Cochrane Database of Systematic Reviews.** 2001.
- 
- Khot UN, Khot MB, Bajzer CT, et al.** *Prevalence of conventional risk factors in patients with coronary heart disease.* **JAMA.** 2003;290:898-904.
-



- 
- Klein S, Burke LE, Bray GA, et al.** *Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.* **Circulation.** 2004;110:2952-2967.
- 
- Kotseva K, Wood D, De Bacquer D, Heidrich J, De Backer G.** *Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II Survey.* **Eur Heart J Suppl.** 2004;27:35-41.
- 
- Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G.** *ACE inhibitor use in people with Myocardial infarction. Summary of evidence from clinical trials.* **Circulation.** 1995;92:3132-3137.
- 
- Law M, Wald N, Morris J.** *Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.* **Health Technol Assess.** 2003;7:1-94.
- 
- Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M.** *Economic burden of cardiovascular diseases in the enlarged European Union.* **Eur Heart J.** 2006;27:1610-1619.
- 
- Leeder S.** *A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies.* New York, NY: Columbia University/The Center for Global Health and Economic Development; 2004.
- 
- Lopez A, Mathers CD, Ezzati M, Jamison D, Murray C.** *Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.* **Lancet.** 2006;367:1747-1757.
- 
- Löwel H, König W, Engel S, Hörmann A, Keil U.** *The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study.* **Diabetologia.** 2000;43:218-226.
- 
- Lubsen J, Wagener G, Kirwan BA, de Brouwer S, ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) Investigators.** *Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hyper tension: the ACTION trial.* **J Hypertens.** 2005;23:641-648.
- 
- Malmberg K, Yusuf S, Gerstein HC, et al; OASIS Registry Investigators.** *Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry.* **Circulation.** 2000;102:1014-1019.
- 
- Manuel DG, Lim J, Tanuseputro P, et al.** *Revisiting Rose: strategies for reducing coronary heart disease.* **BMJ.** 2006;332:659-662.
- 
- McGuire DK, Emanuelsson H, Granger CB et al.** *Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the Gusto-IIb study. Gusto IIb Investigators.* **Eur Heart J.** 2000;21:1750-1758.
- 
- Mendis S, Abegunde D, Yusuf S, et al; WHO-PREMISE (Phase I) Study Group.** *Bull WHO.* 2005;83:820-828.
-

**Bibliography of One Hundred Key Papers**

---

- Mukamal KJ, Nesto RW, Cohen MC, et al.** *Impact of diabetes on long-term survival after acute myocardial infarction: comparability or risk with prior myocardial infarction.* **Diabetes Care.** 2001;24:1422-1427.
- 
- Muntner P, DeSalvo K, Wildman R, Raggi P, He J, Whelton P.** *Trends in the prevalence, awareness, treatment and control of cardiovascular risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke.* **Am J Epidemiol.** 2006;163:913-920.
- 
- Murchie P, Campbell, N, Ritchie LW.** *Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care.* **BMJ.** 2003;326:84-90.
- 
- Nissen S, Tuzcu EM, Libby P, et al.** *CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary heart disease and normal blood pressure. The CAMELOT Study: A Randomized Controlled Trial.* **JAMA.** 2004;292:2217-2226.
- 
- Pearson T, Bales VS, Blair L, et al.** *The Singapore Declaration: forging the will for heart health in the next millennium.* **CVD Prevention.** 1998;1:182-199.
- 
- Pearson T, Laurora I, Chu H, Kafonek S.** *Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals.* **Arch Intern Med.** 2000;160:459-467.
- 
- Post Coronary Artery Bypass Graft Trial Investigators.** *The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.* **N Engl J Med.** 1997;336:153-162.
- 
- Pyörälä K, De Backer G, Graham I, Poole-Wilson PA, Wood D.** *Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension.* **Eur Heart J.** 1994;15:1300-1331.
- 
- Qureshi AI, Suri MF, Guterman LR, Hopkinset LN.** *Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey.* **Arch Intern Med.** 2001;161:1621-1628.
- 
- Reiner Z, Mihatov S, Milicic D, Bergovec M, Planinc D; TASPIC-CRO Study Group Investigators.** *Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).* **Eur J Cardiovasc Prev Rehab.** 2006;13:646-654.
- 
- Rose G.** *The strategy of prevention: lessons from cardiovascular disease.* **Br Med J (Clin Res Ed).** 1981;282:1847-1851.
- 
- Rose G.** *Sick individuals and sick populations.* **Int J Epidemiol.** 1985;14:32-38.
- 
- Rose G.** *The Strategy of Preventive Medicine.* Oxford, UK: Oxford University Press; 1992.
-



- 
- Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering Study Investigators.** *Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.*  
**JAMA.** 2001;285:1711-1718.
- 
- Simes J, Furberg CD, Braunwald E.** *Effects of pravastatin on mortality in people with and without coronary heart disease across a broad range of cholesterol levels. The prospective pravastatin pooling project.*  
**Eur Heart J.** 2002;23:207-215.
- 
- Smith S, Jackson R, Pearson T, et al.** *Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum.*  
**Circulation.** 2004;109:3112-3121.
- 
- Sprangers RLH, Stam F, Smid HEC, et al.** *Multidisciplinary structured lifestyle intervention reduces the estimated risk of cardiovascular morbidity and mortality.*  
**Neth Heart J.** 2004;12:443-449.
- 
- Taylor R, Brown A, Ebrahim S, et al.** *Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomised controlled trials.*  
**Am J Med.** 2004;116:682-692.
- 
- Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D.** *Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.*  
**Curr Med Res Opin.** 2005;21:1389-1399.
- 
- Wilson K, Gibson N, Willan A, Cook D.** *Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies.*  
**Arch Intern Med.** 2000;160:939-944.
- 
- Wood D, De Backer G, Faergeman D, Graham I, Mancina G, Pyörälä K.** *Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.*  
**Eur Heart J.** 1998;19:1434-1503.
- 
- Wood D, Durrington P, Poulter N, McInnes G, Rees A, British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association.** *Joint British recommendations on prevention of coronary heart disease in clinical practice.*  
**Heart.** 1998;80(suppl 2):S1-S29.
- 
- Wood DA, Kotseva K, Connolly S, et al; EUROACTION Study Group.** *Nurse-coordinated multidisciplinary, family based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired cluster randomised controlled trial.*  
**Lancet.** 2008;371:1999-2012.
- 
- World Health Organization.** *Prevention of Coronary Heart Disease. Report of a WHO Expert Committee.*  
Geneva, Switzerland: World Health Organization; 1992. WHO Technical Report Series 678.
- 
- World Health Organization.** *Global Strategy for the Prevention and Control of Noncommunicable Diseases. Report by the Director General.*  
Geneva, Switzerland: World Health Organization; 2000 (Document A53/14).
-

**Bibliography of One Hundred Key Papers**

---

- World Health Organization and Wellcome Trust.** *Secondary Prevention of Non-Communicable Diseases in Low- and Middle-Income Countries Through Community-Based and Health Service Interventions. Report of the Cambridge Meeting.* Switzerland and London, UK: World Health Organization and Wellcome Trust: Geneva; 2001.
- 
- World Health Organization.** *CVD Risk Management Package for Low- and Medium-Resource Settings.* Geneva, Switzerland: World Health Organization; 2002.
- 
- World Health Organization.** *Integrated Management of Cardiovascular Risk: Report of a WHO Meeting, July 2002.* Geneva, Switzerland: WHO Library; 2002.
- 
- World Health Organization.** *The World Health Report 2002: Reducing Risks, Promoting Healthy Life.* Geneva, Switzerland: WHO Library; 2002.
- 
- World Health Organization.** *Reduction of cardiovascular burden through cost-effective integrated Management of Cardiovascular Risk: Addressing Hypertension, Smoking Cessation, and Diabetes.* Geneva, Switzerland: World Health Organization; Report, 9-12 July 2002.
- 
- World Health Organization.** *WHO Framework Convention on Tobacco Control.* Geneva, Switzerland: World Health Organization, 2003.
- 
- World Health Organization.** *Prevention of Recurrent Heart Attacks and Strokes in Low and Middle Income Populations. Evidence-Based Recommendations for Policy Makers and Health Professionals.* Geneva, Switzerland: World Health Organization; 2003.
- 
- World Health Organization.** *World Health Assembly Resolution WHA57.17. Global Strategy on Diet, Physical Activity and Health.* Geneva, Switzerland: World Health Organization; 2004.
- 
- World Health Organization.** *Cardiovascular Disease Prevention. Translating Evidence into Action.* Geneva, Switzerland: World Health Organization, 2005.
- 
- World Health Organization.** *Preventing Chronic Disease: A Vital Investment.* Geneva, Switzerland: World Health Organization; 2005.
- 
- World Health Organization.** *Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk.* Geneva, Switzerland: WHO Library; 2007.
- 
- [www.ptkardio.pl/files//file/luxembourgdeclarationfinal.pdf](http://www.ptkardio.pl/files//file/luxembourgdeclarationfinal.pdf)
- 
- [www.heartcharter.eu](http://www.heartcharter.eu)
- 
- Yusuf S, Hawken S, Ounpuu S, et al.** *Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study.* **Lancet.** 2004;364:937-952.
-

---

# Instructions for authors

## GENERAL INSTRUCTIONS

---

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in English. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All illustrations should be cited in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International (SI)** units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
  1. Ouriel K, Geary K, Green RM, Geary IE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg*. 1990;11:493-496.
  2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation*. 1977;56(suppl II):II161-II164.
  3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher's editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author's responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

## LEAD ARTICLE

---

The lead article should not exceed 30 standard typed pages (7000 to 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of “**10 references of seminal papers**” as well as a separate list of “**100 Key References**” should be provided.

## RESPONDENT ARTICLES

---

Respondent articles should not exceed 15 standard typed pages (3000 to 4000 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

## SEMINAL PAPER SUMMARIES

---

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

## FASCINOMA CARDIOLOGICA ARTICLES

---

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.

---

